Table 3.
List of Current Clinical Studies of Nanoformulations.
| Nano Carriers | Drug | Phase | Outcome Measures | NCT Number | Reference |
|---|---|---|---|---|---|
| EnGeneIC delivery vehicle (EDV) | EGFR-EDV-DOX | I | Determination of a possible phase II dose of drug for recurrent GBM. | NCT02766699 | [168] |
| ILs | C225-IL-DOX | I | Determination of a suitable ratio of C225–IL–DOX concentration. | NCT03603379 | [169] |
| PEGylated Lipososmes | DOX-Trastuzumab | I/II | To determine the safety and tolerability of i.v. administration of the PEGylated liposomes | NCT01386580 | NA |
| Albumin NPs | Rapamycin + Avastin + Radiation | II | To determine progression-free survival (PFS) and overall survival (OS) rate according to response assessment in neuro-oncology (RANO) criteria | NCT03463265 | [171] |
| Cationic Lipososmes | SGT-53 + TMZ | II | To determine six-month PFS and OS, anti-cancer activity, safety, and efficacy of NPs. | NCT02340156 | [170] |
| enzyme-linked immune spots | EGFR-Bi-T | I/II | To determine the maximum tolerated dose (MTD) for eight intrathecal (IT) injections | NCT02521090 | NA |